Plexxikon today announced that updated Phase 1 clinical data of Zelboraf (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA.
- regulatory filing
The combination of dabrafenib and trametinib is safe and effective in BRAF-mutant melanoma.
PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world.
A new report weighs the pros and cons of a sentinel node biopsy for melanoma patients.
The Annual Report on the status of cancer shows a decline in cancer deaths from major cancers including lung, colorectal, prostate, and breast, but some cancer deaths continue to increase specifically for men with melanoma as well as for those with liver, uterine, and pancreatic cancers.
Sorafenib plus chemotherapy did not improve the overall survival of metastatic melanoma patients not previously treated with chemotherapy. The trial results are published in the Journal of Clinical Oncology.
Of 281 cutaneous melanoma patients undergoing inguinal lymph node (ILND) dissection, 14% had wound complications, a rate much lower than those reported in previous single institution studies. In a multivariable model, obesity, and diabetes were significantly associated with wound complications. There was no difference in the rate of reoperation in patients with and without wound complications. The study concludes that the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) appears to underreport the actual incidence of wound complications after ILND.
According to a Kaiser Permanente study, HIV-positive subjects had a 2.1-fold higher risk for basal cell carcinomas and a 2.6-fold higher risk for squamous cell carcinomas, compared to HIV-negative subjects. Squamous cell carcinomas were associated with lower CD4 counts, a measure of immunodeficiency. Prior antiretroviral therapy was not found to be associated with the incidence of either squamous cell carcinomas or basal cell carcinomas
A 2nd publication from a German group also find mutations in TERT, in 74% of non-inherited melanoma cases. Together with the publication from the Harvard group in the same journal, these results are likely a starting point for targeting TERT, the enzyme responsible for adding extra ends onto chromosomes.